CODX vs GILD · rev $3.9M vs P/E 18, rev $29.44B
Co-Diagnostics, Inc. Common Stock (CODX) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
CODX currently screens at market cap $31.4M. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the CODX and GILD stock pages for the full models.
Not investment advice.